Michael J Fox Foundation announces positive results from Allon Therapeutics with davunetide in Parkinson's Disease

The Michael J Foundation announced earlier this month positive preclinical data with davunetide in a mouse model of Parkinson’s Disease.

The drug is in clinical development by Vancouver based Allon Therapeutics for Alzheimer’s disease and other neurodegenerative disorders.

More about this interesting new product, its neuroprotective action and potential to slow down memory loss and cognitive decline can be found on Biotech Strategy Blog.

, , , , , , , , ,

error: Content is protected !!